Skip to main content

Table 2 Vaccination details and characteristics of reinfused mononuclear cells

From: Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response

Reinfused leukapheresis producta

Patient

Tumor weight [gram]

Tumor cell yield

No. of tumor cells/vaccine

No. of nuclear cells

% lympocytes

% CD3+c

%CD4+/%CD8+c

1

11

1.8 × 108

2 × 107

0.9 × 1010

39

81

65/19

2

31

105 × 108

10 × 107

2.1 × 1010

53

79

57/22

3

24

1.9 × 108

1.4 × 107

0.9 × 1010

71

65

52/12

4 b

14

2.8 × 108

n.a.

n.a.

n.a.

n.a.

n.a.

  1. aPBMC were reinfused following 3 days of preparative chemotherapy (cyclophosphamide 350 mg/m2 and fludarabine 20 mg/m2)
  2. bpatient withdrew by choice before the treatment phase
  3. cshown as percentage of lymphocytes
  4. n.a. not applicable